R.E.C.K versus Exparel for pain control during robotic kidney removal
Official title: Efficacy of Ropivacaine Epinephrine Clonidine Ketorolac (R.E.C.K) vs Exparel in Robotic Nephrectomy: a Randomized, Prospective Trial
Run by Wake Forest University Health Sciences · NCT07092566 · Data updated 2026-11-12
This will test whether intraoperative R.E.C.K or Exparel gives better pain control and reduces opioid use in adults having robotic partial or radical nephrectomy.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 170 (estimated) |
| Sponsor | Wake Forest University Health Sciences Academic / other |
| Locations | 1 site (Charlotte, North Carolina) |
| Status | Recruiting |
| Started | November 14, 2025 |
| Main results expected | October 2027 |
| Study ends | October 2027 |
| Registry record updated | July 13, 2026 |
| Trial ID | NCT07092566 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) scheduled for robotic partial or radical nephrectomy who can consent and are not chronic opioid users are ideal candidates.
✕Probably not a fit
Patients who are pregnant, have known allergies to the study drugs, are chronic opioid users, or are deemed unsuitable by the investigator are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center, prospective, randomized phase 3 trial compares intraoperative R.E.C.K (ropivacaine with epinephrine, clonidine, and ketorolac) to Exparel (liposomal bupivacaine) in adults undergoing robotic partial or radical nephrectomy. Investigators will record intraoperative opioid use from the medical record and capture post-anesthesia care unit and inpatient pain scores using the Numerical Rating Scale along with oral and IV opioid and over-the-counter analgesic intake and length of stay. After discharge, participants will log time-stamped pain scores and self-administered analgesics in a provided take-home diary. The goal is to determine whether any improvements with Exparel justify its higher cost compared with the R.E.C.K cocktail.
Why it matters
Potential benefit: If successful, this could lead to better post-operative pain control or reduced opioid consumption and potentially shorter hospital stays for patients undergoing robotic nephrectomy.
How similar studies have gone: Other studies of liposomal bupivacaine and multimodal local anesthetic cocktails have shown mixed results, so a direct randomized comparison in robotic nephrectomy is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Ability to understand and willingness to sign an IRB-approved informed consent 2. Age ≥ 18 years at the time of consent. 3. Planned robotic partial or radical nephrectomy Exclusion Criteria: 1. Determined not to be a candidate to receive R.E.C.K or Exparel per the enrolling investigator 2. Known pregnancy 3. Chronic opioid use within 30 days (as per patient report) prior to randomization (defined as ≥ 30 MME/day) 4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements as determined by the investigator. 5. Known allergy to R.E.C.K. and/or Exparel
Where it's running
-
Levine Cancer
Charlotte, North Carolina, United States Recruiting
Study contacts
- Principal investigator: Roy Ornob, MD — Wake Forest University Health Sciences
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Recovery, quality of life, and physical function after partial or radical nephrectomy
This study tests recovery, quality of life, and physical function before and after nephrectomy to see how patients fare depending on the surgery type.
-
Dexmedetomidine as add-on for refractory cancer pain in palliative care
This study tests whether adding dexmedetomidine helps improve pain control for adults with cancer in palliative care whose pain remains high despite opioids.
-
Two Ways to Help Pain After Breast Surgery: Education-Based Analgesia vs Standard Care
This trial tests whether teaching patients about pain management and using a multimodal pain plan improves pain control and recovery after breast surgery compared with standard care.
-
Virtual Reality Therapy to Improve Arthroplasty Outcomes
This pilot test checks whether using virtual reality during the perioperative period helps knee or hip replacement patients feel better about their care and recover more easily.
-
Suzetrigine for pain relief after knee replacement
This trial tests whether suzetrigine can reduce opioid use after a total knee replacement compared with placebo.
-
Analgesic effects of adding BiFeS block to adductor canal block after ACL reconstruction
This study tests whether adding a BiFeS block to the standard adductor canal block provides better pain relief after ACL reconstruction.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.